Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Maio MCenter for Immuno-Oncology, Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, V.le Bracci, 16, 53100, Siena, Italy. mmaiocro@gmail.com.
Coukos GLausanne Branch, Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
Ferrone SDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Fox BAEarle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Providence Cancer Institute, Providence Portland Medical Center, 4805 NE Glisan, Portland, OR, 97213, USA.
Fridman WHCancer, Immune Control and Escape Team, Cordeliers Research Center, INSERM UMRS 1138, Paris, France.
Garcia PLMerck, ZI de l'Ouriettaz, 1170, Aubonne, Switzerland.
Provendier OLaboratoires Pierre Fabre, 45 Place Abel Gance, 92100, Boulogne-Billancourt, France.
Russo VItalian Network for Tumor Bio-Immunotherapy Foundation, Center for Immuno-Oncology, Istituto Toscano Tumori, University Hospital of Siena, 53100, Siena, Italy.
Rüttinger DRoche Pharma Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
Shalabi ACancer Research Institute, 29 Broadway, New York, NY, 10006-3111, USA.
Trajanoski ZBiocenter, Division of Bioinformatics, Medical University of Innsbruck, 6020, Innsbruck, Austria.
English
A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.